Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cara: Focusing on the periphery

To avoid the side effects of marketed opioid analgesics, Cara Therapeutics Inc. is focusing on specific classes of peripherally selective analgesic compounds targeting kappa opioid receptors, cannabinoid receptors and G protein-coupled receptor heterodimers.

The most extensively used opioid analgesic, morphine, works primarily through activation of the mu opioid receptor in the CNS. Although the CNS action

Read the full 556 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers